Xcout Intel
Alentis Therapeutics
Alentis Therapeutics is a Swiss biotechnology company developing antibody-based medicines that target Claudin-1 (CLDN1), a protein involved in tumor biology and tissue fibrosis. Its therapies are intended for patients with solid tumors and fibrotic diseases, including liver and other organ fibrosis.
Subscribe to see Alentis Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alentis Therapeutics at a glance
Alentis Therapeutics is a biotechnology company headquartered in Switzerland. It has raised at least $248.4M across the 2 funding rounds on record. Its most recent funding round, Series D, raised $181.4M in November 2024. Xcout tracks 9 named people at Alentis Therapeutics, including Mark Pruzanski (Member, CEO).
Alentis Therapeutics leadership
- Mark PruzanskiMember, CEO
- Luca SantarelliChair
- Anna ChenMember
- Brian LiuMember
- Dina ChayaMember
- Naveed Siddiqi, MDMember
3 more named people on record for Alentis Therapeutics, with roles, board committees and tenure — see the full roster →
Alentis Therapeutics funding rounds
At least $248.4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $181.4M | 14 named | |
| — | $67M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Alentis Therapeutics competitors
A few of Alentis Therapeutics's closest competitors — see the full list of competitors and alternatives →
Galecto Biotech is a biotechnology company developing small-molecule inhibitors targeting galectin proteins and related pathways, with applications in fibrotic diseases and cancer. Its products are intended for patients and healthcare providers, particularly in areas with limited treatment options.
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Get Alentis Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alentis Therapeutics in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access